Kurtis E Bachman

US Patent:

20120245180, Sep 27, 2012

Filed:

Sep 28, 2010

Appl. No.:

13/498381

Inventors:

Kurt R. Auger - Collegeville PA, US
Kurtis Earl Bachman - Collegeville PA, US
Tona M. Gilmer - Research Triangle Park NC, US
Joel David Greshock - Collegeville PA, US
Sylvie Laquerre - King of Prussia PA, US
Li Liu - King of Prussia PA, US
Shannon Renae Morris - Research Triangle Park NC, US

Assignee:

GlaxoSmithKline LLC - Philadelphia PA

International Classification:

A61K 31/519
A61P 35/00

US Classification:

51425202

Abstract:

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a novel combination comprising the MEK inhibitor: N-{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the PI3 kinase inhibitor: 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same, and methods of using such combinations in the treatment of cancer.

US Patent:

20130317037, Nov 28, 2013

Filed:

Nov 16, 2011

Appl. No.:

13/885804

Inventors:

Kurtis Earl Bachman - Collegeville PA, US
Joel David Greshock - Collegeville PA, US

Assignee:

GlaxoSmithKline Intellectual Property Development Limited - Middlesex

International Classification:

A61K 31/501
A61K 45/06

US Classification:

51425204

Abstract:

The present invention provides a method of treating a human with cancer comprising detecting at least one mutation in a PIK3CA gene or at least one mutant protein encoded by said PIK3CA gene from at least one first sample from said human and administering to said human an effective amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide or a pharmaceutically acceptable salt thereof in a pharmaceutical composition if said at least one sample has at least one mutant PI3K protein or a mutation in the PIK3CA gene.

US Patent:

20120202822, Aug 9, 2012

Filed:

Oct 12, 2010

Appl. No.:

13/501387

Inventors:

Kurtis Earl Bachman - Collegeville PA, US
Joel David Greshock - Collegeville PA, US
Tona Gilmer - Research Triangle Park NC, US
Sylvie Laquerre - King of Prussia PA, US
Shannon Renae Morris - Research Triangle Park NC, US

International Classification:

A61K 31/506
A61P 35/00

US Classification:

51425204

Abstract:

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a novel combination comprising the MEK inhibitor: N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the PI3 kinase inhibitor: 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same, and methods of using such combinations in the treatment of cancer.

US Patent:

20220288041, Sep 15, 2022

Filed:

Mar 9, 2022

Appl. No.:

17/690380

Inventors:

- Beerse, BE
Kurtis E. Bachman - Chester Springs PA, US
Gerald C. Chu - Philadelphia PA, US
Tatiana Koudriakova - Poway CA, US
David C. Polidori - Rancho Santa Fe CA, US
Gary V. Borzillo - Upper Gwynedd PA, US

International Classification:

A61K 31/437
A61P 1/00
A61P 35/00
C12Q 1/6886
A61K 45/06

Abstract:

Disclosed herein are JAK inhibitors that have low systemic toxicity. In some aspects, the disclosure includes methods for treating disease states, disorders, and conditions mediated by JAK, such as stomacho-intestinal system cancers, including colorectal cancers and familial adenomatous polyposis.

US Patent:

20220194999, Jun 23, 2022

Filed:

Dec 20, 2021

Appl. No.:

17/556019

Inventors:

- Horsham PA, US
Manuel Alejandro Sepulveda - West Windsor NJ, US
Vipul Bhargava - Warrington PA, US
Iqbal S. Grewal - Newtown PA, US
Kurtis Bachman - Wayne PA, US

International Classification:

C07K 14/47
C07K 14/71
C07K 14/725
C12N 15/85
C12N 5/0783
C12N 5/00
C12N 9/14
C12N 9/16
C12N 9/12

Abstract:

Disclosed herein are polypeptide fragments and polynucleotides based on mutant capicua transcriptional repressor (CIC), catenin beta 1 (CTNNB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog B (ERBB2), kirsten rat sarcoma (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), splicing factor 3b subunit 1 (SF3B1), SRY-box transcription factor 17 (SOX17), tumor protein 53 (TP53), and cytomegalovirus (CMV) sequences, vectors, host cells, viruses, methods for generating CD8+ T-cells, and methods of treatment. Also disclosed herein are T-cell receptors (TCRs), polynucleotides, vectors and cells comprising the TCRs, and methods of treatment.